VLST Corporation was founded on the belief that the challenge in developing new therapeutics for the treatment of autoimmune and inflammatory diseases is not a lack of suitable targets but the identification of targets that have true therapeutic potential. VLST’s proprietary platform (the VLST Discovery Platform) is based on a thorough understanding of virulence factors and their function.

VLST has conceived and reduced to practice a streamlined and efficient proprietary proteomics and bioinformatics platform which rapidly yields novel biologic drugs with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders.  The platform harnesses, in its most basic form, the power of evolution in the face of intense natural selection and thus provides a process to choose drug candidates where invested capital can be de-risked through the clinical trial development process.

The VLST Discovery Platform has succeeded in identifying over 500 virulence factors mainly from the genomes of pox, herpes and adenoviruses.  While the screening process is ongoing, VLST has identified over 70 of these virulence factors as having novel interaction with their respective cellular target that may be important in immune modulation.  VLST has selected multiple internal programs to move forward into preclinical development.  VLST has successfully demonstrated activity in multiple in vitro assays and has shown inhibition of immune complex mediated inflammation in vivo with its most advanced program.   VLST continues to prioritize 2 programs to move forward into lead generation and preclinical development.